<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib47">
 <element-citation publication-type="journal" id="sref47">
  <person-group person-group-type="author">
   <name>
    <surname>Kaminskas</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Farrell</surname>
    <given-names>A.T.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Y.-Ch</given-names>
   </name>
   <name>
    <surname>Sridhara</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Pazdur</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension</article-title>
  <source>The Oncologist</source>
  <volume>10</volume>
  <year>2005</year>
  <fpage>176</fpage>
  <lpage>182</lpage>
  <pub-id pub-id-type="doi">10.1634/theoncologist.10-3-176</pub-id>
  <pub-id pub-id-type="pmid">15793220</pub-id>
 </element-citation>
</ref>
